WP's experience at big pharma and rolling out billion dollar drugs gives me a lot reassurance we're heading in the right direction.
Only disappointment is the slow EFS recruitment. May start, we're now in September. That's a big delay for a very small study. Hope these delays don't carry over into the pivotal study.
Eureka report, page-10
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$18.20 |
Change
0.200(1.11%) |
Mkt cap ! $349.8M | |||
| Open | High | Low | Value | Volume |
| $18.00 | $18.20 | $17.65 | $78.15K | 4.366K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 619 | $17.86 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $18.20 | 146 | 1 |
View Market Depth
| Last trade - 16.10pm 08/07/2024 (20 minute delay) ? |
| AVR (ASX) Chart |